COVID-19: Phase 2 human trial of Oxford vaccine may start on August 26 in Pune

The trial may begin from August 26, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India.

Published: 25th August 2020 06:59 PM  |   Last Updated: 25th August 2020 06:59 PM   |  A+A-

vaccine against the coronavirus disease, developed by the Gamaleya Research Institute of Epidemiology and Microbiology. (Photo | AFP)

For representational purpose. (Photo | AFP)


PUNE: Doses of the potential coronavirus vaccine developed by researchers at Oxford University arrived at the Bharti Vidyapeeth's Medical College here for phase-2 human trials on Tuesday, an official said.

The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).

"To start with we have identified five volunteers who will undergo COVID-19 and antibodies test.

Those whosereports are negative will be shortlisted for vaccination on Wednesday," said Dr Sanjay Lalwani, Medical Director, Bharti Vidyapeeth's Medical College and Hospital and Research Centre.

He said the hospital has been given a target of enlisting 300 to 350 volunteers.


Those chosen for receiving a dose of vaccine will be in the age group of 18 to 99 years, he said.

Dr Jeetendra Oswal, deputy medical director of the hospital, said after they are administered the vaccine, the volunteers will be monitored as per the standard trial protocol.

The other hospitals where trials are to be conducted include B J Medical College Hospital in Pune, AIIMS Delhi, Rajendra MemorialResearch Institute of Medical Sciences in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh,Nehru Hospital in Gorakhpur and Andhra Medical College in Visakhapatnam.

SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.



Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp